Clinical Trial Update: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) [Phase 2]

View source ↗

Summary

Phase 2 trial update of nivolumab in patients with Thymoma Type B3 and thymic carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma Type B3

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Thymoma Type B3, Thymic Carcinoma | Phase 2 | Status: UNKNOWN